AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30724059
Drug: Combined sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sea salt-based oral rinse with Xylitol and lysozyme
Trial: 28476814
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2 i.v. on days 1‐8)
Trial: 28476814
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg i.v.) and cisplatin (60 mg/m2 i.v.) plus gemcitabine (1,000 mg/m2 i.v. on days 1‐8)
Trial: 25912693
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard pharmacotherapy)
Trial: 21756210
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam 2 mg (LOR)
Trial: 19364310
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d of oral folic acid
Trial: 16362296
Drug: Paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel with 1,200 mg clindamycin
Trial: 11158211
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid added to antihypertensive therapy
Trial: 11555501
Drug: Erythromycin therapy
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin therapy
Trial: 8426771
Drug: Local isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local isoniazid therapy (50 mg intranodal instillation)
Trial: 3305394
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg b.i.d.
Trial: 3305394
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg b.i.d.
Trial: 3305394
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg t.i.d.
Trial: 27738640
Drug: 5-ALA with
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA with SFC (200 mg 5-ALA/229.42 mg SFC per day)
Trial: 24630878
Drug: Cangrelor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor (500 nM) with 30 mg prasugrel
Trial: 24630878
Drug: Cangrelor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor (500 nM) with 60 mg prasugrel
Trial: 24630878
Drug: Prasugrel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (30 mg) without cangrelor
Trial: 24630878
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg) without cangrelor
Trial: 20329655
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg valsartan (test product)
Trial: 20329655
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg valsartan (reference product)
Trial: 18460998
Drug: Caffeine (CAF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF, 8 mg.kg body wt)
Trial: 12847034
Drug: Pharmacist consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist consultation program (face-to-face medication reviews)
Trial: 19239354
Drug: Immediate switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate switch in therapy
Trial: 19239354
Drug: Delayed switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml)
Trial: 17690017
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) targeting pain catastrophizing
Trial: 15142271
Drug: Industry-sponsored drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Industry-sponsored drug trials
Trial: 9662762
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg twice daily for 3 days
Trial: 9662762
Drug: Erythromycin, 500
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 500 mg four times daily for 7 days
Trial: 9662762
Drug: Cotrimoxazole (trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (trimethoprim 160 mg + sulfamethoxazole 800 mg), twice daily for 7 days
Trial: 8161719
Drug: Tablets (reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (reference)
Trial: 2030299
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy laser treatment (Mid 1500 Irradia laser, wavelength 904 nm, average power output 12 mW, peak value 8.3 W, frequency 70 Hz, pulse train 8000 Hz) applied locally to 6 sites for 30 sec each, total of 10 treatments over 2-3 weeks.
Trial: 2030299
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (details not provided)
Trial: 1250945
Drug: Etifoxine 300
RxNorm normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etifoxine 300 mg
Trial: 1250945
Drug: d‐amphetamine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine 5 mg
Trial: 30914350
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of saffron capsule (200 mg/day)
Trial: 19125045
Drug: Epinastine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinastine 0.05% twice a day plus rewetting drops as required (n = 75)
Trial: 15848653
Drug: DAC-TAC-MMF (tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAC-TAC-MMF (tacrolimus with MMF and daclizumab induction therapy)
Trial: 9385484
Drug: Tiludronate formulation
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate formulation 9O1 (400 mg/d for 84 +/- 2 days)
Trial: 9385484
Drug: Tiludronate formulation
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate formulation 3C1 (400 mg/d for 84 +/- 2 days)
Trial: 8737552
Drug: CRF patients
RxNorm normalized name: CRF
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRF patients on conservative treatment (Gp II)
Trial: 3232477
Drug: Constant infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant infusion of a solution containing glucose (4%), sodium (40 mmol/l), and potassium (20 mmol/l) throughout the observation period
Trial: 3232477
Drug: 5-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hour infusion of 10% glucose daily, with potassium and sodium solution in between
Trial: 28474437
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 0.75% boric acid gel (BA group)
Trial: 28474437
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + placebo gel (placebo group)
Trial: 19363908
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel 0.05% (n=674)
Trial: 19363908
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel microsphere 0.1% (n=376)
Trial: 16469022
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 20 mg twice daily for 12 weeks
Trial: 12964501
Drug: Tropisetron 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 0.05 mg/kg intravenously
Trial: 1828963
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 on days 1, 8, 15, and 22 of radiation therapy
Trial: 6338416
Drug: Propranolol (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1.7 mg/kg)
Trial: 6338416
Drug: Phenobarbital (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (1.3 mg/kg)
Trial: 25675562
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with filiform needle and warm needling therapy combined with positive functional exercise (CZ Dz)
Trial: 19014765
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 microg twice daily (FP monotherapy)
Trial: 19298635
Drug: Montelukast 5
RxNorm normalized name: montelukast 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 5 mg once daily
Trial: 19014765
Drug: Combination fluticasone
RxNorm normalized name: fluticasone, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination fluticasone 100 microg AM and salmeterol twice daily
Trial: 15836887
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rimonabant
Trial: 12841342
Drug: Cerivastatin 0.3
RxNorm normalized name: cerivastatin 0.3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.3 mg at the time of admission (group C+)
Trial: 12841342
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (group C−)
Trial: 10442494
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (290 mg/min/1.73 m2 for 1 h) in normal volunteers
Trial: 7587923
Drug: AO-128 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-128 (0.2 mg) with sucrose
Trial: 7587923
Drug: AO-128 (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-128 (0.03 mg/kg)
Trial: 7587923
Drug: AO-128 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-128 (0.1 mg/kg)
Trial: 26695796
Drug: Low frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequency and intermediate frequency descent type treatment
Trial: 26695796
Drug: Flat type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat type treatment
Trial: 26695796
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency descent type treatment
Trial: 26695796
Drug: Total deafness
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total deafness type treatment
Trial: 21869693
Drug: GW468816 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW468816 (200 mg/d)
Trial: 11465650
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride supplementation 2 g four times a day
Trial: 9467039
Drug: High-dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose leucovorin (LV) administered weekly
Trial: 9467039
Drug: Bimonthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimonthly high-dose LV
Trial: 9467039
Drug: Weekly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly high-dose LV with 5-fluorouracil (5-FU)
Trial: 9467039
Drug: Daily x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily x 5 LV with 5-FU
Trial: 9467039
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies for toxicity (delaying treatment, dose reduction, octreotide)
Trial: 1980266
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 1.1 mg
Trial: 7818588
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 2.2 mg
Trial: 2896104
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 4.4 mg
Trial: 1980266
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride 2.2 mg and 4.4 mg
Trial: 6259722
Drug: Oral Estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Estramustine phosphate
Trial: 6259722
Drug: Intramuscular polyestradiol
RxNorm normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular polyestradiol phosphate plus oral ethinyl estradiol
Trial: 28499420
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (100 mcg)
Trial: 25630368
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplement without additional vitamins and minerals (LNS)
Trial: 25630368
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplement with additional vitamins and minerals (LNS-VM)
Trial: 18355326
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine without polysorbate-20 (R)
Trial: 18355326
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine with polysorbate-20 (T)
Trial: 18355326
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of insulin glargine
Trial: 8607393
Drug: Flecainide 200
RxNorm normalized name: flecainide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 200 mg (n = 97)
Trial: 8607393
Drug: Propafenone 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 450 mg (n = 103)
Trial: 8607393
Drug: Flecainide (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (maximum 300 mg/day)
Trial: 8607393
Drug: Propafenone (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (maximum 900 mg/day)
Trial: 28623638
Drug: Taurolock™‐HEP500 (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolock™‐HEP500 (heparin 500 IU/mL, taurolidine, citrate 4%) after each hemodialysis session
Trial: 25640807
Drug: Intensive/triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive/triple antiplatelet therapy for one month
Trial: 24171182
Drug: Propranolol 90
RxNorm normalized name: propranolol hydrochloride 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 90 mg and Stabilization Splint (SS)
Trial: 24171182
Drug: Propranolol 90
RxNorm normalized name: propranolol hydrochloride 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 90 mg and Non-Occlusal Splint (NOS)
Trial: 17550044
Drug: Hydroxyzine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (2 mg/kg 2 h before treatment and 1 mg/kg 20 min before treatment)
Trial: 17550044
Drug: Midazolam (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Trial: 17550044
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Trial: 14762748
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I surgery (hyoid suspension, palatal surgery, and/or genioglossus advancement)
Trial: 8056717
Drug: Pimobendan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (2.5 or 5.0 mg/day)
Trial: 3241254
Drug: Adrenaline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (15 mg/kg per min)
Trial: 3241254
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% NaCl, 5.4 ml/h)
Trial: 29804902
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Trial: 29804902
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Trial: 23938374
Drug: Chemotherapy treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy treated women
Trial: 23938374
Drug: Treatment related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment related toxicities (mucositis, diarrhea, decreased absolute neutrophil count, elevated glucose, cholesterol)
Trial: 21449676
Drug: Antidepressants other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants other than paroxetine
Trial: 18155871
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg twice daily, could be reduced to 50 mg twice daily)
Trial: 10867087
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (specifics not provided)
Trial: 10867087
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (specifics not provided)
Trial: 8416053
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of Protirelin (synthetic TRH) intravenously
Trial: 2939126
Drug: Increased plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased plasma folate to 13 ng/ml or above
Trial: 30561229
Drug: SB5 administered
RxNorm normalized name: SB5+
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB5 administered via autoinjector (AI)
Trial: 30561229
Drug: SB5 administered
RxNorm normalized name: SB5+
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB5 administered via prefilled syringe (PFS)
Trial: 25436296
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg ramosetron 1 hour before ingestion of a test meal (200 kcal per 200 mL, containing 100 mg 13C acetate)
Trial: 21953277
Drug: WHR-associated gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHR-associated gene variant LYPLAL1/SLC30A10 rs4846567 G allele
Trial: 19495810
Drug: Aqua lymphatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua lymphatic therapy (ALT) for 3 months in addition to self-management therapy
Trial: 19495810
Drug: Aqua lymphatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua lymphatic therapy (ALT)
Trial: 9459339
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg enalaprilat intravenously prior to thrombolysis
Trial: 7629560
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 g, intramuscularly administered)
Trial: 2535067
Drug: mesoglycan (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesoglycan (72 mg/day orally)
Trial: 26755506
Drug: New sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sedation policy (sequential administration of melatonin, hydroxyzine, and chloral hydrate)
Trial: 26755506
Drug: Old sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old sedation policy (sole administration of chloral hydrate)
Trial: 25913070
Drug: Nimorazole (NIM)
RxNorm normalized name: nimorazole
DrugBank: Nimorazole (DB12172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimorazole (NIM) administered at a dose of 1.2g/m2, 90 minutes before the first daily radiotherapy (RT) fraction.
Trial: 22004601
Drug: Full drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full drug-eluting stent (DES) coverage (n = 90)
Trial: 22004601
Drug: Spot drug-eluting
RxNorm normalized name: Cold Spot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spot drug-eluting stent (DES) coverage (n = 89)
Trial: 16608954
Drug: docetaxel, 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel, 35 mg/m(2) IV infusion (D(35)) on days 1, 8, and 15 every 4 weeks
Trial: 16608954
Drug: docetaxel, 40
RxNorm normalized name: Docetaxel, 40 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel, 40 mg/m(2) IV (D(40)) on days 1 and 8 every 3 weeks
Trial: 16608954
Drug: docetaxel, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel, 75 mg/m(2) IV (D(75)) on day 1 every 3 weeks